Funding momentum ProofPilot has recently secured funding of 7.7M and expanded through the Lokavant acquisition, signaling strong investor confidence and growth velocity. This presents an opportunity to discuss scalable partnerships and enterprise collaborations that align with rapid expansion.

Acquisition momentum The acquisition of Lokavant indicates a consolidation of clinical trial intelligence capabilities. Sales conversations can explore integrated data and analytics offerings, leveraging ProofPilot's end-to-end CXP with predictive insights to attract sponsors seeking unified patient experience and trial optimization.

Clinical experience focus As an end-to-end Clinical Experience Platform, ProofPilot targets sponsor teams responsible for patient recruitment, retention, and site engagement. Position solutions that enhance patient-centric workflows, branding consistency, and streamlined site communications to reduce burden and speed trial timelines.

Leadership expansion Key appointments such as the VP of Clinical Strategy & Solutions and the Chief Customer Officer indicate a emphasis on strategy, customer success, and enterprise adoption. This opens doors for high-touch pilots, co-development opportunities, and long-term strategic deployments with sponsors.

Market positioning With revenue in the mid-range and a growing ecosystem of competitors in patient experience and trial analytics, emphasize ProofPilot’s integrated platform, recent funding, and events like CORE Symposium to differentiate through thought leadership, case studies, and measurable improvements in recruitment and engagement metrics.